Lymphocryptoviruses: EBV and Its Role in Human Cancer

  • Santosh Kumar Upadhyay
  • Hem Chandra Jha
  • Abhik Saha
  • Erle S. Robertson
Chapter
First Online:
Part of the Current Cancer Research book series (CUCR)

Abstract

Lymphocryptoviruses (LCVs) are gamma 1-herpesviruses well known for infecting Old-World primates. They display a biphasic life cycle usually with a lifelong persistence, which is typically asymptomatic in their host, and are capable of inducing malignancies. Epstein–Barr virus (EBV) is the most well-studied LCV and is the only member known to cause infection in humans. EBV is the causative agent of infectious mononucleosis and is associated with a number of human malignancies including, Burkitt’s lymphoma (BL), Hodgkin’s disease (HD), nasopharyngeal carcinoma (NPC), and posttransplant lymphoproliferative diseases (PTLD). Interestingly, many of the Old-World primates are known to have the pathological equivalents of these diseases associated with respective LCVs. The EBV genome provides the genetic validation for similarities between EBV infection in human and LCV infections of Old-World primates. Here, we discuss the molecular aspects of host–pathogen interaction in regard to EBV-induced diseases with a particular focus on tumorigenesis, as a representative of the general pathologies associated with LCV-induced malignancies. The role of various EBV proteins in establishment of infection, persistence, and tumorigenesis, as well as the numerous host-signaling pathways targeted by the viral molecules for carrying out these phenomena are explored. Furthermore, the available preferences for diagnosis and treatment modalities for EBV-induced pathologies are discussed in this chapter.

Keywords

Hematopoietic Stem Cell Transplantation Oral Hairy Leukoplakia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Ackermann M (2006) Pathogenesis of gammaherpesvirus infections. Vet Microbiol 113:211–222PubMedGoogle Scholar
  2. Allan GJ, Inman GJ, Parker BD, Rowe DT, Farrell PJ (1992) Cell growth effects of Epstein–Barr virus leader protein. J Gen Virol 73(Pt 6):1547–1551PubMedGoogle Scholar
  3. Allday MJ (2009) How does Epstein–Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt’s lymphoma? Semin Cancer Biol 19:366–376PubMedGoogle Scholar
  4. Allday MJ, Farrell PJ (1994) Epstein–Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol 68:3491–3498PubMedGoogle Scholar
  5. Artavanis-Tsakonas S, Matsuno K, Fortini ME (1995) Notch signaling. Science 268:225–232PubMedGoogle Scholar
  6. Aster JC, Pear WS, Blacklow SC (2008) Notch signaling in leukemia. Annu Rev Pathol 3:587–613PubMedGoogle Scholar
  7. Baer R et al (1984) DNA sequence and expression of the B95-8 Epstein–Barr virus genome. Nature 310:207–211PubMedGoogle Scholar
  8. Baichwal VR, Sugden B (1988) Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein–Barr virus. Oncogene 2:461–467PubMedGoogle Scholar
  9. Basseres DS, Baldwin AS (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25:6817–6830PubMedGoogle Scholar
  10. Bodescot M, Brison O, Perricaudet M (1986) An Epstein–Barr virus transcription unit is at least 84 kilobases long. Nucleic Acids Res 14:2611–2620PubMedGoogle Scholar
  11. Borggrefe T, Oswald F (2009) The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci 66:1631–1646PubMedGoogle Scholar
  12. Bornkamm GW, Hammerschmidt W (2001) Molecular virology of Epstein–Barr virus. Philos Trans R Soc Lond B Biol Sci 356:437–459PubMedGoogle Scholar
  13. Brunstein CG et al (2006) Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108:2874–2880PubMedGoogle Scholar
  14. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R (1998) Epstein–Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405–411PubMedGoogle Scholar
  15. Callahan J, Aster J, Sklar J, Kieff E, Robertson ES (2000) Intracellular forms of human NOTCH1 interact at distinctly different levels with RBP-jkappa in human B and T cells. Leukemia 14:84–92PubMedGoogle Scholar
  16. Carville A, Mansfield KG (2008) Comparative pathobiology of macaque lymphocryptoviruses. Comp Med 58:57–67PubMedGoogle Scholar
  17. Chen SY, Lu J, Shih YC, Tsai CH (2002) Epstein–Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J Virol 76:9556–9561PubMedGoogle Scholar
  18. Choudhuri T, Verma SC, Lan K, Robertson ES (2006) Expression of alpha V integrin is modulated by Epstein–Barr virus nuclear antigen 3C and the metastasis suppressor Nm23-H1 through interaction with the GATA-1 and Sp1 transcription factors. Virology 351:58–72PubMedGoogle Scholar
  19. Cohen JI, Wang F, Kieff E (1991) Epstein–Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 65:2545–2554PubMedGoogle Scholar
  20. Cotter MA 2nd, Robertson ES (2000) Modulation of histone acetyltransferase activity through interaction of Epstein–Barr nuclear antigen 3C with prothymosin alpha. Mol Cell Biol 20:5722–5735PubMedGoogle Scholar
  21. Damania B, Jung JU (2001) Comparative analysis of the transforming mechanisms of Epstein–Barr virus, Kaposi’s sarcoma-associated herpesvirus, and Herpesvirus saimiri. Adv Cancer Res 80:51–82PubMedGoogle Scholar
  22. Dantuma NP, Masucci MG (2003) The ubiquitin/proteasome system in Epstein–Barr virus latency and associated malignancies. Semin Cancer Biol 13:69–76PubMedGoogle Scholar
  23. Dawson CW, Tramountanis G, Eliopoulos AG, Young LS (2003) Epstein–Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem 278:3694–3704PubMedGoogle Scholar
  24. de Oliveira DE, Ballon G, Cesarman E (2010) NF-kappaB signaling modulation by EBV and KSHV. Trends Microbiol 18:248–257PubMedGoogle Scholar
  25. Decaussin G, Sbih-Lammali F, de Turenne-Tessier M, Bouguermouh A, Ooka T (2000) Expression of BARF1 gene encoded by Epstein–Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 60:5584–5588PubMedGoogle Scholar
  26. Deng Z et al (2003) The CBP bromodomain and nucleosome targeting are required for Zta-directed nucleosome acetylation and transcription activation. Mol Cell Biol 23:2633–2644PubMedGoogle Scholar
  27. Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF, Kieff E (1998) Role of the TRAF binding site and NF-kappaB activation in Epstein–Barr virus latent membrane protein 1-induced cell gene expression. J Virol 72:7900–7908PubMedGoogle Scholar
  28. Devergne O et al (1996) Association of TRAF1, TRAF2, and TRAF3 with an Epstein–Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 16:7098–7108PubMedGoogle Scholar
  29. Dolyniuk M, Pritchett R, Kieff E (1976a) Proteins of Epstein–Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein–Barr virus. J Virol 17:935–949PubMedGoogle Scholar
  30. Dolyniuk M, Wolff E, Kieff E (1976b) Proteins of Epstein–Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus. J Virol 18:289–297PubMedGoogle Scholar
  31. Ehlers B et al (2010) Lymphocryptovirus phylogeny and the origins of Epstein–Barr virus. J Gen Virol 91:630–642PubMedGoogle Scholar
  32. Ekholm SV, Reed SI (2000) Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12:676–684PubMedGoogle Scholar
  33. Eliopoulos AG, Blake SM, Floettmann JE, Rowe M, Young LS (1999) Epstein–Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol 73:1023–1035PubMedGoogle Scholar
  34. Eliopoulos AG et al (1996) CD40-induced growth inhibition in epithelial cells is mimicked by Epstein–Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13:2243–2254PubMedGoogle Scholar
  35. Eliopoulos AG, Young LS (1998) Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein–Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16:1731–1742PubMedGoogle Scholar
  36. Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1:702–703PubMedGoogle Scholar
  37. Epstein MA, Henle G, Achong BG, Barr YM (1965) Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt’s lymphoma. J Exp Med 121:761–770PubMedGoogle Scholar
  38. Floettmann JE, Ward K, Rickinson AB, Rowe M (1996) Cytostatic effect of Epstein–Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. Virology 223:29–40PubMedGoogle Scholar
  39. Fries KL, Miller WE, Raab-Traub N (1999) The A20 protein interacts with the Epstein–Barr virus latent membrane protein 1 (LMP1) and alters the LMP1/TRAF1/TRADD complex. Virology 264:159–166PubMedGoogle Scholar
  40. Fruehling S, Longnecker R (1997) The immunoreceptor tyrosine-based activation motif of Epstein–Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235:241–251PubMedGoogle Scholar
  41. Giles RH, Peters DJ, Breuning MH (1998) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14:178–183PubMedGoogle Scholar
  42. Gires O et al (1997) Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule. EMBO J 16:6131–6140PubMedGoogle Scholar
  43. Given D, Yee D, Griem K, Kieff E (1979) DNA of Epstein–Barr virus. V. Direct repeats of the ends of Epstein–Barr virus DNA. J Virol 30:852–862PubMedGoogle Scholar
  44. Gomez-Marquez J, Rodriguez P (1998) Prothymosin alpha is a chromatin-remodelling protein in mammalian cells. Biochem J 333(Pt 1):1–3PubMedGoogle Scholar
  45. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E (1994) The Epstein–Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci USA 91:7568–7572PubMedGoogle Scholar
  46. Grundhoff AT et al (1999) Characterization of DP103, a novel DEAD box protein that binds to the Epstein–Barr virus nuclear proteins EBNA2 and EBNA3C. J Biol Chem 274:19136–19144PubMedGoogle Scholar
  47. Gulley ML (2001) Molecular diagnosis of Epstein–Barr virus-related diseases. J Mol Diagn 3:1–10PubMedGoogle Scholar
  48. Hammerschmidt W, Sugden B (1989) Genetic analysis of immortalizing functions of Epstein–Barr virus in human B lymphocytes. Nature 340:393–397PubMedGoogle Scholar
  49. Harada S, Yalamanchili R, Kieff E (2001) Epstein–Barr virus nuclear protein 2 has at least two N-terminal domains that mediate self-association. J Virol 75:2482–2487PubMedGoogle Scholar
  50. Hatzivassiliou E, Miller WE, Raab-Traub N, Kieff E, Mosialos G (1998) A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. J Immunol 160:1116–1121PubMedGoogle Scholar
  51. Hayward SD (2004) Viral interactions with the Notch pathway. Semin Cancer Biol 14:387–396PubMedGoogle Scholar
  52. Heslop HE (2009) How I treat EBV lymphoproliferation. Blood 114:4002–4008PubMedGoogle Scholar
  53. Heslop HE, Brenner MK, Rooney CM (1994) Donor T cells to treat EBV-associated lymphoma. N Engl J Med 331:679–680PubMedGoogle Scholar
  54. Heslop HE et al (1996) Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551–555PubMedGoogle Scholar
  55. Hitt MM et al (1989) EBV gene expression in an NPC-related tumour. EMBO J 8:2639–2651PubMedGoogle Scholar
  56. Hsu H, Xiong J, Goeddel DV (1995) The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81:495–504PubMedGoogle Scholar
  57. Huen DS, Henderson SA, Croom-Carter D, Rowe M (1995) The Epstein–Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549–560PubMedGoogle Scholar
  58. Ikeda M, Ikeda A, Longan LC, Longnecker R (2000) The Epstein–Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. Virology 268:178–191PubMedGoogle Scholar
  59. Izumi KM, Cahir McFarland ED, Ting AT, Riley EA, Seed B, Kieff ED (1999) The Epstein–Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Mol Cell Biol 19:5759–5767PubMedGoogle Scholar
  60. Izumi KM, Kaye KM, Kieff ED (1997) The Epstein–Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci USA 94:1447–1452PubMedGoogle Scholar
  61. Izumi KM, Kieff ED (1997) The Epstein–Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 94:12592–12597PubMedGoogle Scholar
  62. Jiang WQ, Szekely L, Wendel-Hansen V, Ringertz N, Klein G, Rosen A (1991) Co-localization of the retinoblastoma protein and the Epstein–Barr virus-encoded nuclear antigen EBNA-5. Exp Cell Res 197:314–318PubMedGoogle Scholar
  63. Johannsen E et al (2004) Proteins of purified Epstein–Barr virus. Proc Natl Acad Sci USA 101:16286–16291PubMedGoogle Scholar
  64. Johnson DG, Walker CL (1999) Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39:295–312PubMedGoogle Scholar
  65. Karran L, Gao Y, Smith PR, Griffin BE (1992) Expression of a family of complementary-strand transcripts in Epstein–Barr virus-infected cells. Proc Natl Acad Sci USA 89:8058–8062PubMedGoogle Scholar
  66. Kaschka-Dierich C et al (1976) Intracellular forms of Epstein–Barr virus DNA in human tumour cells in vivo. Nature 260:302–306PubMedGoogle Scholar
  67. Kashuba E et al (2010) Epstein–Barr virus-encoded EBNA-5 forms trimolecular protein complexes with MDM2 and p53 and inhibits the transactivating function of p53. Int J Cancer 128:817–825Google Scholar
  68. Kaul R, Murakami M, Choudhuri T, Robertson ES (2007) Epstein–Barr virus latent nuclear antigens can induce metastasis in a nude mouse model. J Virol 81:10352–10361PubMedGoogle Scholar
  69. Kaul R, Murakami M, Lan K, Choudhuri T, Robertson ES (2009) EBNA3C can modulate the activities of the transcription factor Necdin in association with metastasis suppressor protein Nm23-H1. J Virol 83:4871–4883PubMedGoogle Scholar
  70. Kempkes B, Pich D, Zeidler R, Sugden B, Hammerschmidt W (1995) Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein–Barr virus DNA. J Virol 69:231–238PubMedGoogle Scholar
  71. Kieff ED, Rickinson AB (2007) Epstein–Barr Virus and its replication. In: Knipe DM, Howley PM (eds) Fields virology, 5th edn. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
  72. Kilger E, Kieser A, Baumann M, Hammerschmidt W (1998) Epstein–Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 17:1700–1709PubMedGoogle Scholar
  73. Kim HR, Jeong JA, Park CH, Lee SK, Lee WK, Jang YS (2002) A role for cell cycle proteins in the serum-starvation resistance of Epstein–Barr virus immortalized B lymphocytes. Biochem Cell Biol 80:407–413PubMedGoogle Scholar
  74. Klein G, Klein E, Kashuba E (2010) Interaction of Epstein–Barr virus (EBV) with human B-lymphocytes. Biochem Biophys Res Commun 396:67–73PubMedGoogle Scholar
  75. Knight JS, Lan K, Subramanian C, Robertson ES (2003) Epstein–Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 77:4261–4272PubMedGoogle Scholar
  76. Knight JS, Robertson ES (2004) Epstein–Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. J Virol 78:1981–1991PubMedGoogle Scholar
  77. Knight JS, Sharma N, Robertson ES (2005a) Epstein–Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci USA 102:18562–18566PubMedGoogle Scholar
  78. Knight JS, Sharma N, Robertson ES (2005b) SCFSkp2 complex targeted by Epstein–Barr virus essential nuclear antigen. Mol Cell Biol 25:1749–1763PubMedGoogle Scholar
  79. Kuehnle I et al (2000) CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95:1502–1505PubMedGoogle Scholar
  80. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N (1998) Expression of the Epstein–Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 95:11963–11968PubMedGoogle Scholar
  81. Kumar P, Saha A, Robertson ES (2010) Epstein–Barr virus hijacks cell-cycle machinery. Microbe 5:251–256Google Scholar
  82. Kuppers DA, Lan K, Knight JS, Robertson ES (2005) Regulation of matrix metalloproteinase 9 expression by Epstein–Barr virus nuclear antigen 3C and the suppressor of metastasis Nm23-H1. J Virol 79:9714–9724PubMedGoogle Scholar
  83. Kuppers R (2003) B cells under influence: transformation of B cells by Epstein–Barr virus. Nat Rev Immunol 3:801–812PubMedGoogle Scholar
  84. Kutok JL, Wang F (2006) Spectrum of Epstein–Barr virus-associated diseases. Annu Rev Pathol Mech Dis 1:375–404Google Scholar
  85. Kwiatkowski B, Chen SY, Schubach WH (2004) CKII site in Epstein–Barr virus nuclear protein 2 controls binding to hSNF5/Ini1 and is important for growth transformation. J Virol 78:6067–6072PubMedGoogle Scholar
  86. Lacoste V, Lavergne A, de Thoisy B, Pouliquen JF, Gessain A (2010) Genetic diversity and molecular evolution of human and non-human primate Gammaherpesvirinae. Infect Genet Evol 10:1–13PubMedGoogle Scholar
  87. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM (1992) The Epstein–Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 267:24157–24160PubMedGoogle Scholar
  88. Lambert SL, Martinez OM (2007) Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 179:8225–8234PubMedGoogle Scholar
  89. Laux G, Perricaudet M, Farrell PJ (1988) A spliced Epstein–Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J 7:769–774PubMedGoogle Scholar
  90. Leao M, Anderton E, Wade M, Meekings K, Allday MJ (2007) Epstein–Barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt’s lymphoma cells. J Virol 81:248–260PubMedGoogle Scholar
  91. Lee CP et al (2007) Epstein–Barr virus BGLF4 kinase induces premature chromosome condensation through activation of condensin and topoisomerase II. J Virol 81:5166–5180PubMedGoogle Scholar
  92. Levitskaya J et al (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685–688PubMedGoogle Scholar
  93. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG (1997) Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein–Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 94:12616–12621PubMedGoogle Scholar
  94. Lindahl T, Adams A, Bjursell G, Bornkamm GW, Kaschka-Dierich C, Jehn U (1976) Covalently closed circular duplex DNA of Epstein–Barr virus in a human lymphoid cell line. J Mol Biol 102:511–530PubMedGoogle Scholar
  95. Lo AK et al (2007) Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci USA 104:16164–16169PubMedGoogle Scholar
  96. Longnecker R (2000) Epstein–Barr virus latency: LMP2, a regulator or means for Epstein–Barr virus persistence? Adv Cancer Res 79:175–200PubMedGoogle Scholar
  97. Longnecker R, Druker B, Roberts TM, Kieff E (1991) An Epstein–Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol 65:3681–3692PubMedGoogle Scholar
  98. Longnecker R, Kieff E (1990) A second Epstein–Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol 64:2319–2326PubMedGoogle Scholar
  99. Mainou BA, Everly DN Jr, Raab-Traub N (2005) Epstein–Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Oncogene 24:6917–6924PubMedGoogle Scholar
  100. Mannick JB, Cohen JI, Birkenbach M, Marchini A, Kieff E (1991) The Epstein–Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol 65:6826–6837PubMedGoogle Scholar
  101. Marchini A, Tomkinson B, Cohen JI, Kieff E (1991) BHRF1, the Epstein–Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication. J Virol 65:5991–6000PubMedGoogle Scholar
  102. Merlo A et al (2010) The interplay between Epstein–Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 95:1769–1777PubMedGoogle Scholar
  103. Miller CL et al (1995) Integral membrane protein 2 of Epstein–Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2:155–166PubMedGoogle Scholar
  104. Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F (1997) An animal model for acute and persistent Epstein–Barr virus infection. Science 276:2030–2033PubMedGoogle Scholar
  105. Moody CA et al (2005) Modulation of the cell growth regulator mTOR by Epstein–Barr virus-encoded LMP2A. J Virol 79:5499–5506PubMedGoogle Scholar
  106. Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261–291PubMedGoogle Scholar
  107. Murai Y et al (2001) Study on the role of G1 cyclins in Epstein–Barr virus-associated human lymphomas maintained in severe combined immune deficiency (SCID) mice. Int J Cancer 92:232–239PubMedGoogle Scholar
  108. Nanbo A, Inoue K, Adachi-Takasawa K, Takada K (2002) Epstein–Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt’s lymphoma. EMBO J 21:954–965PubMedGoogle Scholar
  109. Nitsche F, Bell A, Rickinson A (1997) Epstein–Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J Virol 71:6619–6628PubMedGoogle Scholar
  110. Nonkwelo C, Skinner J, Bell A, Rickinson A, Sample J (1996) Transcription start sites downstream of the Epstein–Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol 70:623–627PubMedGoogle Scholar
  111. O’Nions J, Allday MJ (2004) Deregulation of the cell cycle by the Epstein–Barr virus. Adv Cancer Res 92:119–186PubMedGoogle Scholar
  112. O’Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L (1997) Biology and adoptive cell therapy of Epstein–Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 157:195–216PubMedGoogle Scholar
  113. Obaya AJ, Sedivy JM (2002) Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci 59:126–142PubMedGoogle Scholar
  114. Park CH et al (2004) Latent membrane protein 1 of Epstein–Barr virus plays an important role in the serum starvation resistance of Epstein–Barr virus-immortalized B lymphocytes. J Cell Biochem 91:777–785PubMedGoogle Scholar
  115. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ (2009) Epstein–Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5:e1000492PubMedGoogle Scholar
  116. Portal D, Rosendorff A, Kieff E (2006) Epstein–Barr nuclear antigen leader protein coactivates transcription through interaction with histone deacetylase 4. Proc Natl Acad Sci USA 103:19278–19283PubMedGoogle Scholar
  117. Powell JL, Bunin NJ, Callahan C, Aplenc R, Griffin G, Grupp SA (2004) An unexpectedly high incidence of Epstein–Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant 33:651–657PubMedGoogle Scholar
  118. Raab-Traub N (2009) Epstein–Barr virus transforming proteins: biologic properties and contribution to oncogenesis; DNA tumor viruses. Springer, HeidelbergGoogle Scholar
  119. Radkov SA, Bain M, Farrell PJ, West M, Rowe M, Allday MJ (1997) Epstein–Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol 71:8552–8562PubMedGoogle Scholar
  120. Radkov SA et al (1999) Epstein–Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 73:5688–5697PubMedGoogle Scholar
  121. Rastelli J, Hömig-Hölzel C, Seagal J, Müller W, Hermann AC, Rajewsky K, Zimber-Strobl U (2008) LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood 111:1448–1455PubMedGoogle Scholar
  122. Rechsteiner MP et al (2008) Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein–Barr virus infection. J Virol 82:1739–1747PubMedGoogle Scholar
  123. Rickinson AB, Kieff E (2001) Epstein–Barr Virus. In: Knipe DM, Howley PM (eds) Fields Virology, 4th edn. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
  124. Rivadeneira ED et al (1999) A novel Epstein–Barr virus-like virus, HV(MNE), in a Macaca nemestrina with mycosis fungoides. Blood 94:2090–2101PubMedGoogle Scholar
  125. Rivailler P, Cho YG, Wang F (2002a) Complete genomic sequence of an Epstein–Barr virus-related herpesvirus naturally infecting a new world primate: a defining point in the evolution of oncogenic lymphocryptoviruses. J Virol 76:12055–12068PubMedGoogle Scholar
  126. Rivailler P, Jiang H, Cho YG, Quink C, Wang F (2002b) Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein–Barr virus animal model. J Virol 76:421–426PubMedGoogle Scholar
  127. Robertson E, Kieff E (1995) Reducing the complexity of the transforming Epstein–Barr virus genome to 64 kilobase pairs. J Virol 69:983–993PubMedGoogle Scholar
  128. Robertson ES (1997) The Epstein–Barr virus EBNA 3 protein family as regulators of transcription. Epstein–Barr Virus Rep 4:143–150Google Scholar
  129. Robertson ES, Tomkinson B, Kieff E (1994) An Epstein–Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro. J Virol 68:1449–1458PubMedGoogle Scholar
  130. Roizmann B, Desrosiers RC, Fleckenstein B, Lopez C, Minson AC, Studdert MJ (1992) The family Herpesviridae: an update. The Herpesvirus Study Group of the International Committee on Taxonomy of Viruses. Arch Virol 123:425–449PubMedGoogle Scholar
  131. Rooney CM et al (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549–1555PubMedGoogle Scholar
  132. Ruf IK, Rhyne PW, Yang C, Cleveland JL, Sample JT (2000) Epstein–Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J Virol 74:10223–10228PubMedGoogle Scholar
  133. Saha A, Bamidele A, Murakami M, Robertson ES (2010a) EBNA3C attenuates the function of p53 through interaction with the inhibitor of growth family proteins, 4 and 5. J Virol 85:2079–2088PubMedGoogle Scholar
  134. Saha A et al (2010b) Epstein–Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog 7(2):e1001275Google Scholar
  135. Saha A, Kaul R, Murakami M, Robertson ES (2010c) Tumor viruses and cancer biology: modulating signaling pathways for therapeutic intervention. Cancer Biol Ther 10:961–978PubMedGoogle Scholar
  136. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES (2009) Epstein–Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 83:4652–4669PubMedGoogle Scholar
  137. Sakai T et al (1998) Functional replacement of the intracellular region of the Notch1 receptor by Epstein–Barr virus nuclear antigen 2. J Virol 72:6034–6039PubMedGoogle Scholar
  138. Sandberg M, Hammerschmidt W, Sugden B (1997) Characterization of LMP-1’s association with TRAF1, TRAF2, and TRAF3. J Virol 71:4649–4656PubMedGoogle Scholar
  139. Schmidtko J et al (2002) Posttransplant lymphoproliferative disorder associated with an Epstein–Barr-related virus in cynomolgus monkeys. Transplantation 73:1431–1439PubMedGoogle Scholar
  140. Sheng W, Decaussin G, Sumner S, Ooka T (2001) N-terminal domain of BARF1 gene encoded by Epstein–Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2. Oncogene 20:1176–1185PubMedGoogle Scholar
  141. Shiama N (1997) The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol 7:230–236PubMedGoogle Scholar
  142. Silins SL, Sculley TB (1994) Modulation of vimentin, the CD40 activation antigen and Burkitt’s lymphoma antigen (CD77) by the Epstein–Barr virus nuclear antigen EBNA-4. Virology 202:16–24PubMedGoogle Scholar
  143. Smith PR et al (2000) Structure and coding content of CST (BART) family RNAs of Epstein–Barr virus. J Virol 74:3082–3092PubMedGoogle Scholar
  144. Straathof KC, Bollard CM, Rooney CM, Heslop HE (2003) Immunotherapy for Epstein–Barr virus-associated cancers in children. Oncologist 8:83–98PubMedGoogle Scholar
  145. Subramanian C, Cotter MA 2nd, Robertson ES (2001) Epstein–Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: a molecular link to cancer metastasis. Nat Med 7:350–355PubMedGoogle Scholar
  146. Suzan F, Ammor M, Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345:1000PubMedGoogle Scholar
  147. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG (1993) EBNA-5, an Epstein–Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 90:5455–5459PubMedGoogle Scholar
  148. Takada K, Nanbo A (2001) The role of EBERs in oncogenesis. Semin Cancer Biol 11:461–467PubMedGoogle Scholar
  149. Takeshita H et al (1999) Matrix metalloproteinase 9 expression is induced by Epstein–Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol 73:5548–5555PubMedGoogle Scholar
  150. Tong X, Drapkin R, Reinberg D, Kieff E (1995a) The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein–Barr virus nuclear protein 2. Proc Natl Acad Sci USA 92:3259–3263PubMedGoogle Scholar
  151. Tong X, Drapkin R, Yalamanchili R, Mosialos G, Kieff E (1995b) The Epstein–Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol Cell Biol 15:4735–4744PubMedGoogle Scholar
  152. Tong X, Wang F, Thut CJ, Kieff E (1995c) The Epstein–Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein. J Virol 69:585–588PubMedGoogle Scholar
  153. Tsai DE et al (2008) EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 8:1016–1024PubMedGoogle Scholar
  154. Uchida J et al (1999) Mimicry of CD40 signals by Epstein–Barr virus LMP1 in B lymphocyte responses. Science 286:300–303PubMedGoogle Scholar
  155. Valentine R et al (2010) Epstein–Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation. Mol Cancer 9:1PubMedGoogle Scholar
  156. van Esser JW et al (2002) Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99:4364–4369PubMedGoogle Scholar
  157. Wang D, Liebowitz D, Kieff E (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831–840PubMedGoogle Scholar
  158. Wang D et al (1988) Epstein–Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 62:4173–4184PubMedGoogle Scholar
  159. Wang L, Grossman SR, Kieff E (2000) Epstein–Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci USA 97:430–435PubMedGoogle Scholar
  160. Wang Z et al (2010) STAT3 activation induced by Epstein–Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 and ERK signaling. Eur J Cancer 46:2996–3006PubMedGoogle Scholar
  161. Wei H, Zhou MM (2010) Viral-encoded enzymes that target host chromatin functions. Biochim Biophys Acta 1799:296–301PubMedGoogle Scholar
  162. Werneburg BG, Zoog SJ, Dang TT, Kehry MR, Crute JJ (2001) Molecular characterization of CD40 signaling intermediates. J Biol Chem 276:43334–43342PubMedGoogle Scholar
  163. Wilson JB, Bell JL, Levine AJ (1996) Expression of Epstein–Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 15:3117–3126PubMedGoogle Scholar
  164. Wu DY, Kalpana GV, Goff SP, Schubach WH (1996) Epstein–Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. J Virol 70:6020–6028PubMedGoogle Scholar
  165. Wu DY, Krumm A, Schubach WH (2000) Promoter-specific targeting of human SWI-SNF complex by Epstein–Barr virus nuclear protein 2. J Virol 74:8893–8903PubMedGoogle Scholar
  166. Yenamandra SP et al (2010) Epstein–Barr virus encoded EBNA-3 binds to vitamin D receptor and blocks activation of its target genes. Cell Mol Life Sci 67:4249–4256PubMedGoogle Scholar
  167. Yi F et al (2009) Epstein–Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388:236–247PubMedGoogle Scholar
  168. Young LS, Murray PG (2003) Epstein–Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22:5108–5121PubMedGoogle Scholar
  169. Young LS, Rickinson AB (2004) Epstein–Barr virus: 40 years on. Nat Rev Cancer 4:757–768PubMedGoogle Scholar
  170. Zheng H, Li LL, Hu DS, Deng XY, Cao Y (2007) Role of Epstein–Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol 4:185–196PubMedGoogle Scholar
  171. zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, van den Brule AJ (2000) Unique transcription pattern of Epstein–Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res 60:2745–2748PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Santosh Kumar Upadhyay
    • 1
    • 2
  • Hem Chandra Jha
    • 1
    • 2
  • Abhik Saha
    • 1
    • 2
  • Erle S. Robertson
    • 1
    • 2
  1. 1.Department of Microbiology and Abramson Comprehensive Cancer CenterUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  2. 2.Abramson Comprehensive Cancer CenterUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations